Media

October 9, 2025

Ascenta Capital Announces Final Close of $325 Million Inaugural Fund to Back Development-Stage Biotechs

September 10, 2025

Odyssey Therapeutics heralds $213M Series D to strengthen clinical portfolio

May 14, 2025

AbbVie pays ADARx $335M cash for next-gen siRNA options

October 23, 2024

Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C

September 06, 2024

OrsoBio Announces Oversubscribed $67 Million Series B to Accelerate Obesity and Metabolic Portfolio

July 16, 2024

Cardurion Builds Cardiovascular Pipeline with $260M Series B Financing

July 16, 2024

Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund

July 16, 2024

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline....

June 18, 2024

How two academic chemists turned San Diego startup Iambic into an AI force

June 18, 2024

Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs

March 18, 2024

NVIDIA GTC 2024 -- Official Keynote Intro

February 12, 2024

Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence

December 5, 2023

Odyssey raises epic $101M to push programs off to clinical sea

December 05, 2023

Odyssey Therapeutics Announces $101 Million Series C Financing

December 5, 2023

Gary Glick’s Odyssey raises $101M Series C as first immunology drugs approach the clinic

October 4 , 2023

Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C

October 3, 2023

Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered.

October 3, 2023

Fresh off massive fundraising, ADARx preps 3rd clinical program and mulls IPO.

August 21, 2023

Adarx to use $200M in financing to advance its clinical programs.

August 10, 2023

ADARx secures $200m to advance clinical programmes.

January 21, 2023

Jan. 20 Quick Takes: Moderna vets pick ADARx for new VC’s debut investment.

January 20, 2023

ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324.